You choose it

Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation

Possible combination research: co-study with probiotics has been proposed, though this is speculative
A randomized, double-blind, placebo-controlled trial in 191 older adults (75 years) with moderate vitamin B 12 deficiency (serum cobalamin concentrations of 107-210 pmol/L) without anemia provided participants with 1 mg/day of cyanocobalamin for one year (94)
Multifactorial interventions involving exercise, diet, and diabetes treatment are effective in preventing frailty
The oral capsule format is of particular interest in this area, since the swallowed peptide is delivered directly into the gastrointestinal tract, where much of this research activity has historically been localised and where the compounds reported stability in gastric conditions is most relevant